Business
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
Calgary, Alberta--(Newsfile Corp. - October 4, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix...
About this update from Resverlogix Corp.
[{"type":"text","content":"Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyCalgary, Alberta--(Newsfile Corp. - October 4, 2023) - Resverlogix Corp. (TSX: RVX) (\"Resverlogix\") today announced the publication of a peer-reviewed article, entitled \"Apabetalone, a Clinical-stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells\" in the journal Biomedicines.\"The beneficial effect of apabetalone highlighted in these models of facioscapulohumeral muscular dystrophy in combination with the impressive clinical and safety data in metabolic diseases, present further evidence to support apabetalone's potential benefit in the treatment of patients with this disease,\" said Donald McCaffrey, President and CEO at Resverlogix. \"This exciting program will be added to a growing list of our compassionate use efforts that include post COVID-19 conditions, vascular dementia and chronic kidney disease, in addition to our upcoming core program Phase 3 clinical trial, BETonMACE2.\"The article is published online HERE.Publication Highlights Include:Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent muscular dystrophies, affecting hundreds of thousands of people worldwide, and there are currently no approved therapeutics.The disease is caused by the inappropriate expression of a specific protein, double homeobox 4 (DUX4) in patient's muscle cells.DUX4 activation leads to cell death, inflammation, atrophy, and loss of muscle function.Cultured muscle cells from FSHD patients were used to evaluate the potential of apabetalone to counter the negative effects of DUX4 activation.Apabetalone treatment inhibited DUX4 activity and reversed its hallmark gene expression in these cells.Treatment with apabetalone also did not negatively affect the differentiation or viability of the muscle cells, important indicators of the drug's safety.\"Currently available treatment options for FSHD lessen the burden of symptoms, but do nothing to address the disease's root cause,\" said Dr. Ewelina Kulikowski, Chief Scientific Officer at Resverlogix. \"By directly inhibiting DUX4 activity in muscle cells, apabetalone has the potential to significantly improve the lives of FSHD patients.\"About Apabetalone Apabetalone (RVX-208), is a first-in-class, small molecule, ...